



1Q 2026 Financial Results

| May 4, 2026

Forward looking statements & safe harbor

Certain matters discussed in this presentation are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates;

the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geopolitical conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control.

The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this presentation, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

This presentation contains statements regarding the Company’s observations based upon the reported clinical data. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about the Company’s industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Neither we nor any other person makes any representation as to the accuracy or completeness of such data or undertakes any obligation to update such data after the date of this presentation. In addition, these projections, assumptions and estimates are necessarily subject to a high degree of uncertainty and risk.

Axsome, AUVELITY, SUNOSI, SYMBRAVO, and MoSEIC, are trademarks or registered trademarks of Axsome Therapeutics, Inc. or its affiliates. Except as with respect to AUVELITY and SUNOSI for their approved indications, the development products referenced herein have not been approved by the FDA.

Our Mission

Develop and deliver
transformative medicines
to improve the brain
health of millions of
individuals



A singular CNS platform

3

marketed products

 **Auvelity**[®]
(dextromethorphan HBr and bupropion HCl)
extended-release tablets 45mg/105mg

**SUNOSI**[®]
(solriamfetol) (IV)

**SYMBRAVO**[®]
(meloxicam and rizatriptan)
20 mg/10 mg tablets

4

approved indications



MDD

21M+



AADAD

5M+



EDS in OSA
or narcolepsy

22M+



Migraine

39M+

Singular

pipeline

6

novel product candidates

10

high-unmet-need indications

Significant advancements across our industry-leading pipeline

AUVELITY



NEW APPROVED INDICATION

Agitation Associated with Dementia due to Alzheimer's Disease


PIPELINE PROGRESS

- NDA for AXS-12 for cataplexy in narcolepsy submitted to the FDA
- Initiated CLARITY Phase 3 trial of solriamfetol in MDD with EDS symptoms
- Initiated FORWARD Phase 3 trial of AXS-14 in fibromyalgia
- Phase 2 trial-enabling activities for AXS-17 in epilepsy underway
- Expanded pipeline with potential first-in-class PDE10A inhibitor for schizophrenia and Tourette syndrome

UPCOMING MILESTONES

- Initiation of pivotal Phase 2/3 trial of AXS-05 in smoking cessation (2Q 2026)
- Initiation of Phase 3 trial of solriamfetol in children with ADHD (2Q 2026)
- Initiation of Phase 3 trial of solriamfetol in adolescents with ADHD (2Q 2026)
- Topline results of the ENGAGE Phase trial of solriamfetol in binge eating disorder (2H 2026)
- Topline results of the SUSTAIN Phase 3 trial of solriamfetol in shift work disorder (2027)

Leading neuroscience pipeline with deep stratification



Advancing new frontiers across 10 serious CNS conditions

Psychiatry

Smoking cessation

34M+ adults in the U.S. smoke cigarettes¹ **~70%** of smokers say they want to quit²

ADHD

22M+ people in the U.S. live with ADHD³ **>90%** of pediatric ADHD persist into adulthood⁴

Binge eating disorder

7M+ people impacted in the U.S.⁵ **1** FDA-approved treatment

MDD with EDS symptoms

~50% of MDD patients have concomitant EDS⁶ **0** FDA-approved treatments

Schizophrenia

~3.7M people in the U.S. have schizophrenia and related psychotic disorders⁷

Neurology

Narcolepsy

185K people in the U.S. are affected by narcolepsy⁸ **~70%** of patients suffer from cataplexy⁹

Fibromyalgia

17M+ people in the U.S. have fibromyalgia¹⁰ **>50%** of patients discontinue treatment in the first year¹¹

Shift work disorder

15M+ working Americans may be impacted¹²⁻¹⁴ **0** new medications approved since 2007


Epilepsy

~3.4M people in the U.S. live with epilepsy¹⁵ **>1/3** of patients don't respond to treatment¹⁶

Tourette syndrome

~0.6% of children in the U.S. may suffer from Tourette syndrome¹⁷

Expansive portfolio positioned to generate >\$18B in peak sales




Advancing the frontiers of brain health



Broad commercial portfolio

Three innovative medicines improving patient outcomes and driving durable growth



Expanding AUVELITY

Second approved indication expanding reach and accelerating growth



Industry-leading CNS pipeline

Potential first-in-class, best-in-class treatments across ten serious CNS conditions

Financial Highlights

1Q 2026 financial highlights

\$191M

Total revenue
1Q 2026

57%

YoY growth

1Q 2026 REVENUE

YoY GROWTH

 **Auvelity**[®]
(dextromethorphan HBr and bupropion HCl)
extended-release tablets 45mg/105mg

\$153.2M

+59%

 **SUNOSI**
(solriamfetol) (IV)

\$33.9M

+34%


SYMBRAVO[®]
(meloxicam and rizatriptan)
20 mg/10 mg tablets

\$4.1M

—


AUVELITY® quarterly net revenue performance

Auvelity®
(dextromethorphan HBr and bupropion HCl)
extended-release tablets 45mg/105mg



AUVELITY 1Q 2026 net produce revenue of \$153.2M (59% YoY growth)

SUNOSI[®] quarterly net revenue performance



SUNOSI 1Q 2026 net produce revenue of \$33.9M (34% YoY growth)



1Q 2026 financial summary

\$ millions	1Q 2026	1Q 2025	% Change
Net Product Revenue	\$191.2	\$121.5	57%
AUVELITY	\$153.2	\$96.2	59%
SUNOSI*	\$33.9	\$25.2	34%
SYMBRAVO	\$4.1	—	—
R&D Expense	\$52.7	\$44.8	18%
SG&A Expense	\$185.0	\$120.8	53%

Financial snapshot



Runway to reach ***cash flow positivity***, based on the current operating plan

Cash Balance: (as of March 31, 2026)	\$305.1M
Debt (Face Value): (as of March 31, 2026)	\$190M
Market Cap: (as of May 1, 2026)	\$10.6B
Shares Outstanding: (as of March 31, 2026)	51.4M
Options, RSUs, and Others Outstanding*:	8.8M

Commercial Update

Executing across a broad commercial portfolio with significant combined peak sales potential

 **Auvelity**[®]
(dextromethorphan HBr and bupropion HCl)
extended-release tablets 45mg/105mg

- Expanding adoption in primary care
- ~630 sales representatives to increase reach across primary care, psychiatry, neurology, and geriatrics in MDD and Alzheimer's disease agitation

 **SUNOSI**[®]
(solriamfetol) 

- Continued steady growth across OSA and narcolepsy
- High patient satisfaction supporting durable utilization

SYMBRAVO[®]
(meloxicam and rizatriptan)
20 mg/10 mg tablets

- Expanded payer coverage with ~17M additional commercial lives
- Increasing sales force to ~150 representatives

~\$9.5B total commercial opportunity across marketed products

First-in-class treatment for agitation associated with Alzheimer's disease



Efficacy demonstrated in short-term and long-term studies

- Only approved treatment for agitation associated with dementia due to Alzheimer's disease demonstrating substantial symptom improvement and statistically significantly longer time to relapse



Distinct safety and tolerability profile

- Most common adverse reactions[†] were dizziness and dyspepsia
- 1.3% of patients treated with AUVELITY discontinued due to an adverse event, the same rate as placebo
- No new boxed warning



Addressing a serious unmet medical need

- Approved through Priority Review following Breakthrough Therapy designation



First and only oral NMDA receptor antagonist and sigma-1 receptor agonist for MDD in adults^{1,2}



Only oral antidepressant with rapid-acting efficacy reflected in FDA label¹



Rapid symptom improvement starting at week 1, sustained at week 6 vs. placebo¹



Rapid remission as early as week 2, sustained and increased vs. control through week 6³



Continued momentum driven by expanding adoption in primary care



EXPANDING PRESCRIBER BASE

~60,000

Unique writers since launch

~35%

Primary care share of prescribers



GROWING PATIENT REACH

>300,000

Patients treated since launch

>223,000

TRx in 1Q 2026 (+35% YoY)



EARLIER-LINE UTILIZATION


~56%

First- or second-line use

~50%

Monotherapy use


Quarterly TRx Launch to Date



Source: Symphony METYS

Strong commercial foundation for expansion into Alzheimer's disease agitation

COMMERCIAL FOUNDATION



LAUNCH READINESS

- Educational efforts across community and long-term care settings
- Broad insurance coverage and comprehensive patient support
- Commercial launch anticipated in approximately one month

First and only dopamine and norepinephrine reuptake inhibitor for EDS associated with narcolepsy or OSA¹



First and only wakefulness promoting agent proven to improve wakefulness through 9 hours¹



90% of patients reported feeling better with SUNOSI 150 mg²



Improvements in cognitive functioning vs. placebo demonstrated in clinical trials



Sustained growth and impact



CONTINUED PRESCRIBER REACH

~16,500

Unique writers since launch



STEADY PATIENT GROWTH

>103,000

Patients treated since launch

~54,000

TRx in 1Q 2026 (+16% YoY)



STRONG MARKET ACCESS

~83%

Total covered lives


~96%

Commercial covered lives

~60%

Medicare and Medicaid covered lives

Quarterly nTRx Launch to Date



Source: Symphony METYS. nTRx normalizes number of pills in each Trx for 30-day period.

Novel, oral, rapidly-absorbed, multi-mechanistic approach for the acute treatment of migraine¹



Single, oral dose provided rapid migraine pain freedom and return to normal functioning within 2 hours¹



Superior efficacy demonstrated across a broad range of migraine severity (mild, moderate, severe)¹



Harnesses Axsome's MoSEIC™ rapid absorption technology to target multiple pathways underlying a migraine attack



Momentum building through trial, access, and reach

SYMBRAVO[®]
 (meloxicam and rizatriptan)
 20 mg/10 mg tablets



INITIAL PRESCRIBER ADOPTION

~3,400

Unique writers since launch

~60%

Neurologist share of prescribers



EARLY UPTAKE

>13,500

New patients since launch

>17,000

TRx in 1Q 2026 (+36% QoQ)



EXPANDING MARKET ACCESS

~57%

Total covered lives

~56%

Commercial covered lives

~57%

Medicare and Medicaid covered lives




INCREASED SALES FORCE

~150

Sales representatives supporting broader reach in primary care

Weekly TRx Launch to Date



Source: Symphony METYS

Development Pipeline

AXS-05 for smoking cessation

70% of smokers
want to quit²



Only 3-5% who attempt to quit without
assistance are successful for 6-12 months²



~34M adults in the U.S.
smoke cigarettes, ~50% of
whom live with a smoking-
related disease¹



Single **largest cause of
preventable disease** and
death in the U.S., accounting
for nearly 1 in 5 deaths¹



Associated with over **\$300
billion** in annual costs in
the U.S.¹

Solriamfetol

Unique pharmacology supports potential utility in a broad range of CNS conditions


Solriamfetol was initially developed as a dopamine and norepinephrine reuptake inhibitor (DNRI) with wake-promoting effects




Preclinical and clinical evidence^{1,2} suggest TAAR1 plays a role in neuropsychiatric conditions related to the dysregulation of monoaminergic transmission



Multimodal activity of solriamfetol selectively inhibits the reuptake of dopamine and norepinephrine and exhibits agonist activity at TAAR1 receptors in the brain



Solriamfetol Phase 3 development programs



ADHD

- ✓ **Positive** FOCUS Phase 3 trial in adults with ADHD (N=516)
- **Initiation** of two Phase 3 trials in children and adolescents with ADHD on track for 2Q 2026

MDD with EDS

- **Initiated** CLARITY Phase 3 trial in MDD with EDS symptoms

BED

- **Ongoing** ENGAGE Phase 3 trial in adults with binge eating disorder (N=450)
- Topline data anticipated in 2H 2026

SWD

- **Ongoing** SUSTAIN Phase 3 trial in adults with shift work disorder (N=450)
- Topline data anticipated in 2027



Approved in EDS associated with OSA and narcolepsy

Solriamfetol

Attention deficit hyperactivity disorder (ADHD)



Chronic neurobiological and developmental disorder affecting an estimated **~22M** people in the U.S.¹, including ~7M children aged 3-17 years old²




Characterized by a persistent pattern of inattention and/or hyperactive-impulsive behaviors³



Associated with significant impairment in social, academic, and occupational functioning and development³

Statistically significant improvements in ADHD symptoms with solriamfetol treatment

FOCUS Phase 3 Trial^a



Primary endpoint: Change from baseline in AISRS total score at Week 6

17.7-point

reduction in the AISRS total score at Week 6 with solriamfetol vs. 14.3-point reduction with placebo (p=0.039)^b

Significantly greater percentage of patients receiving solriamfetol achieved a clinical response^b vs. placebo (p=0.024)^c

Significant improvements in overall ADHD severity vs. placebo (CGI-S, p=0.017)^c

Well tolerated with a side effect profile consistent with the established safety profile of solriamfetol

MDD with excessive daytime sleepiness symptoms



Major depressive disorder (MDD) is one of the most common mental disorders in the U.S., impacting **~21M** adults each year^{2,3}




Approximately **50% of patients** with MDD also experience excessive daytime sleepiness (EDS)⁴, for which there are no approved treatments



MDD patients with EDS have difficulty maintaining wakefulness, resulting in **impaired daily functioning and increased safety risks**

CLARITY Phase 3 trial design

CLARITY Phase 3 Trial



Key eligibility criteria

- 18-65 years of age with diagnosis of MDD (DCM-5 criteria)
- Excessive daytime sleepiness symptoms

Primary endpoint

- Time from randomization to relapse of depressive symptoms

Binge eating disorder

>7 million people in the U.S. have BED¹



BED is 1.75x more common in women than in men¹



Binge eating disorder (BED) is the **most common** eating disorder, affecting 2.8% of adults and 1.6% of adolescents in the US^{1,2}



BED is **thought to involve** issues with food reward processing, impulse control, cognitive control, and appetite regulation^{1,3}



Unmet medical need associated with a 2- to 3-fold **increased risk** of psychiatric and medical comorbidities⁴

Evaluating solriamfetol as a potential treatment for binge eating disorder



Solriamfetol inhibits the reuptake of dopamine and norepinephrine, neurotransmitters implicated in the pathophysiology of binge eating disorder¹⁻³



Pre-clinical and clinical data support potential effects of solriamfetol on appetite, food consumption, and weight^{4,5}

ENGAGE Phase 3 Trial

Screening (4 weeks) | Baseline | Double-blind Phase (12 weeks) | Follow-up (1 week)

1:1:1 R
N=450

Solriamfetol (150 mg)

Solriamfetol (300 mg)

Placebo

Key eligibility criteria

- 18-55 years of age with diagnosis of BED (DSM-5)

Primary endpoint

- Change from baseline in days with binge eating episodes

Shift work disorder

~15 million U.S. workers may suffer from SWD

10-43% have SWD^{1,3}

Approximately 1 in 3 people working in the U.S. work an alternate shift²



Shift work disorder (SWD) is a combination of excessive sleepiness during wakefulness and persistent insomnia during daytime sleep when working outside a 7 a.m. to 6 p.m. workday¹




Shift work has long been associated with multiple serious health complaints and a 23% greater risk of sustaining a work-related injury⁴⁻⁵



No new medications approved since 2007 and considerable residual sleepiness reported when medication is used⁶

Evaluating solriamfetol as a potential treatment for shift work disorder

SUSTAIN Phase 3 Trial



Key eligibility criteria

- 18-65 years of age with diagnosis of SWD (ICSD-2 or ICSD-3)

Primary endpoint

- Change from baseline in MWT

AXS-12 (reboxetine)

Novel pharmacological approach for the treatment of narcolepsy

Norepinephrine and dopamine play important roles in sleep-wake regulation (both) and in maintaining muscle tone during wakefulness (norepinephrine)¹⁻³




The loss of orexin input inhibits the production of these neurotransmitters^{1,2}

- Decreased norepinephrine signaling is thought to contribute to **cataplexy, EDS, and cognitive impairment**^{1,4,7}
- Decreased dopamine signaling is thought to contribute to **EDS and cognitive impairment**^{1,4}



AXS-12 **inhibits the reuptake** of both neurotransmitters, improving both norepinephrine and cortical dopamine signaling in the brain



Narcolepsy



Rare and debilitating neurological condition that affects approximately **185,000** people in the U.S.¹





Characterized by **cataplexy**, excessive daytime sleepiness (EDS), hypnagogic hallucinations, sleep paralysis, and disrupted nocturnal sleep²⁻⁴



Up to **70%** of patients suffer from cataplexy, or the sudden reduction or loss of muscle tone while awake⁵

Rapid and robust reductions in cataplexy with AXS-12 treatment



*Ratio of change in the AXS-12 group divided by the ratio of change in the placebo group (rate ratio of 1 = no difference)

New Drug Application (NDA) submitted to the FDA

AXS-14 (esreboxetine)

Novel pharmacological approach for the management of fibromyalgia (FM)


Fibromyalgia pain is thought to be partially caused by **dysregulated signaling** in the descending analgesic system



Norepinephrine, one of the key neurotransmitters in this pathway, has predominantly **pain-inhibitory effects**



AXS-14 is a potent and selective enantiomer of racemic reboxetine that **inhibits the reuptake of norepinephrine**, resulting in increased norepinephrine activity and decreased pain signaling



Fibromyalgia

An estimated **~17 million** people in the U.S. are impacted by fibromyalgia¹



Chronic and debilitating neurological pain syndrome resulting from a dysfunction in central pain processing^{2,3}



Characterized by widespread musculoskeletal pain, fatigue, disturbed sleep, mood disturbances, cognitive impairment, and hypersensitivity to sensory stimuli^{4,5}






Associated with substantial physical disability and reduced emotional and social wellbeing, financial burden, and reduced quality of life^{2,3}

Rapid and robust improvements in fibromyalgia symptoms with AXS-14 treatment

Pain reduction^a

Phase 3 efficacy results (N=1,122)




✓ Efficacy and safety of AXS-14 compared to placebo evaluated in >1,000 individuals with fibromyalgia across Phase 2 and Phase 3 clinical trials for up to 14 weeks

✓ Rapid and significant reductions in pain scores, improvements in patient-reported global functioning, fatigue, and overall symptom severity

FORWARD Phase 3 trial ongoing

FORWARD Phase 3 trial design

FORWARD Phase 3 Trial



Key eligibility criteria

- ≥ 18 years of age with diagnosis of fibromyalgia

Primary endpoint

- Time from randomization to loss of therapeutic response

AXS-17

Novel oral GABA_A receptor α 2,3 subtype-selective positive allosteric modulator (PAM) for epilepsy

Epilepsy is a chronic and debilitating neurological disorder affecting **~3.4M** people in the U.S.¹



Despite currently available treatment options, **<1/3** of patients do not respond to treatment²



AXS-17 was safe and well tolerated in clinical studies in >700 patients to date and demonstrated compelling anti-convulsant activity in preclinical seizure models



Phase 2 trial-enabling activities underway

AXS-20

Potential first-in-class selective PDE10A inhibitor for neuropsychiatric conditions

Schizophrenia

- Demonstrated a favorable safety and tolerability profile in clinical studies in >360 individuals to date
- Completed a proof-of-concept Phase 2 trial in patients with schizophrenia
- Phase 3 trial-enabling activities for AXS-20 in schizophrenia anticipated in 2026

~3.7M people in the U.S. have schizophrenia and related psychotic disorders¹

Tourette syndrome

- Evaluating AXS-20 as a potential treatment for Tourette syndrome

1 out of every 162 children in the U.S. may suffer from Tourette syndrome²

Strong intellectual property and barriers to entry

AUVELITY

- Protected by a robust patent estate extending to at least 2043; Multiple pending
- Proprietary drug product formulation and methods of treatment

SYMBRAVO

- Protected by a robust patent estate extending to at least 2045; Multiple pending
- Proprietary MoSEIC™ formulation, drug product formulation, and methods of treatment

SUNOSI

- Protected by a robust patent estate extending to at least 2042; Multiple pending
- Proprietary drug substance, drug product formulation, and methods of treatment

AXS-12

- Orphan Drug Designation
- Claims extending to at least 2039
- 9 issued U.S. patents and 6 issued O.U.S. patents; Multiple pending
- Proprietary drug substance, drug product formulation, and methods of treatment

AXS-05

- Claims extending to at least 2043
- >150 issued U.S. patents and >130 issued O.U.S. patents; Multiple pending
- Proprietary drug product formulation and methods of treatment

AXS-14

- Claims extending to at least 2045
- 1 issued U.S. patent; Multiple pending
- Proprietary drug substance, drug product formulation, and methods of treatment

Leadership team

Management

Herriot Tabuteau, MD
Founder & CEO



Nick Pizzie, CPA, MBA
Chief Financial Officer



Mark Jacobson, MA
Chief Operating Officer



Hunter Murdock, JD
General Counsel



Ari Maizel
Chief Commercial Officer



Board of Directors

Roger Jeffs, PhD
CEO, Liquidia Corporation
Former President, Co-CEO, Director United Therapeutics Corp.
Prior positions at Amgen and Burroughs Wellcome

Mark Saad
CEO, NuLids, LLC
Former COO of the Global Healthcare Group at UBS

Susan Mahony, PhD
Former SVP of Eli Lilly and President Lilly Oncology
Prior positions at BMS, Amgen and Schering-Plough

Mark Coleman, MD
Medical Director, National Spine and Pain Centers
Diplomat of the American Board of Anesthesiology

Herriot Tabuteau, MD
Chairman

Thank you

